-
Professor Jakob Kather Elaborates on the Evolution and Future Prospects of AI in Hematologic Oncology丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was held in a hybrid format, both online and in-person, gathering top experts and scholars from the global hematology community. The conference focused on the deep integration of cutting-edge technology and clinical practice, with the application of Artificial Intelligence (AI) being one of the core topics. Professor…
-
Professor John Mascarenhas Details Breakthrough Safety and Efficacy Data of INCA33989 in Patients with ET丨EHA 2025
The 2025 European Hematology Association (EHA) Annual Meeting was recently held, bringing together top global experts in the field of hematologic malignancies to discuss the latest research findings and future directions. In the highly anticipated “Late-Breaking Abstract” session, Professor John Mascarenhas from the Icahn School of Medicine at Mount Sinai presented clinical study data on…
-
HCT Frailty Scale Pioneers a New Paradigm in Pre-transplant Assessment: Precisely Predicting Prognosis and Optimizing Patient Management丨EHA 2025
Opportunities and Challenges in Allogeneic Transplantation: The Urgent Need for Precise Assessment Professor Maria Queralt Salas pointed out at the beginning of her report that as a potentially curative therapy,…
-
Professor Shaji Kumar Details the Breakthrough Application of Talquetamab plus Teclistamab in Relapsed/Refractory Multiple Myeloma with Extramedullary
Extramedullary Disease: The “Solid Ice” of Multiple Myeloma Treatment Multiple myeloma is a hematologic malignancy characterized by the abnormal proliferation of plasma cells in the bone marrow. However, when these…
-
In-depth Analysis of the Background and Core Issues of the EHA Guidelines for Mild-to-Moderate Hemophilia A/B丨2025 EHA Guidelines Meeting
Introduction: Challenging Traditional Cognition, The Systematic Layout of the EHA Guidelines Committee At the beginning of the meeting, Professor Steffen Koschmieder from Aachen, Germany, a member of the EHA Guidelines…
-
EHA-EMN 2025 Guidelines Reshape the Multiple Myeloma Treatment Landscape: Quadruplet Regimens and Immunotherapies Lead a New Era丨EHA 2025
Guideline Update Background: Addressing the Unprecedented Complexity of Treatment Choices At the beginning of the meeting, Professor Peter Sonneveld, President of EHA-EMN, delivered the opening remarks. He pointed out that…
-
ESMO–EHA Release Joint Clinical Practice Guidelines for Peripheral T-Cell Lymphoma, Defining a New Standard in Diagnosis and Treatment丨EHA 2025
Development and Core Framework of the New Guidelines: A Decade of Refinement At the beginning of the meeting, Professor Massimo Federico reviewed the developmental history of PTCL guidelines. He noted…
-
Redefining “Stem Cell”: Professor Sten Eirik Jacobsen Unveils New Mechanisms of Lineage Restriction in Hematopoietic Stem Cells丨EHA 2025
The human hematopoietic system is responsible for vital functions of substance transport and immune defense, with an astonishing cell turnover rate—approximately 90% of all cells are replaced daily by the…
Connecting Medical Expertise through Media